NATTO - 10 Year Vitamin K study published


10 year study published in December 2017, "Prevalence and Effects of Functional Vitamin K Insufficiency: The PREVEND Study"

"Importantly, a low vitamin K status is not only a clinically relevant risk factor for adverse health outcomes, but may also be a modifiable risk factor. Given the availability of vitamin K supplements, vitamin K insufficiency seems an attractive target for preventive intervention."

http://www.mdpi.com/2072-6643/9/12/1334
Herman*
04.01.2018 kl 16:26 2643

Antar at MenaQ7 ble brukt, dette er jo et studie som er utført av samme "gjengen" i Nederland som har holdt på med Vitamin K2 studier i en mannsalder.


No, this was not an intervention study (no supplement was given).
Instead they show that over a 10-year period, people with vitamin K insufficiency is more likely to die both from all-cause and cardiovascular mortality.
Redigert 04.01.2018 kl 16:34 Du må logge inn for å svare
Herman*
04.01.2018 kl 16:57 2647

Aha, thanks for correcting me...:-)

You are welcome :-)

Another important excerpt from the study -
"We demonstrated that functional vitamin K insufficiency is common in the general population and occurs even more frequently
among the elderly and subjects with hypertension, type 2 diabetes, CKD, and CVD."

Here is yet another study on Vitamin K, published in January 2018. Authors include Leon Schurgers and Cees Vermeer.

http://www.mdpi.com/2072-6643/10/1/46/htm
14.01.2018 kl 13:23 2409

Disse studiene måler ikke VitK direkte, kun en markør for VitK-balanse, og skiller ikke mellom K1 og K2. Likefullt er det interessant og er en ny indikasjon på at VitK har betydning for kardiovaskulær helse.

VITAMIN K2 FOR HEART AND BONE HEALTH

Researchers at the University of California in Los Angeles have begun to understand the link between atherosclerosis and osteoporosis. They seem to be linked to certain regulators, such as osteopontin and matrix GLA-protein, which affect both bone health and the health of the arteries. A protein known as morphogenetic protein-2 was thought to be present only in bone but has been found in the tissue that makes up atherosclerotic plaques.

http://masjcs.com/vitamin-k2-heart-bone-health/
Herman*
13.02.2018 kl 22:43 2096

Denne er helt ny:
Konklusjonen først: . "VK2 exerted effective antitumor effects in vivo, and VK2 nanoemulsions modified with sialic acid-cholesterol conjugate enhanced the antitumor activity, suggesting that these VK2 may be promising agents for the prevention or treatment of tumor in patients".

https://www.ncbi.nlm.nih.gov/pubmed/28849577

Evaluation of the antitumor effects of vitamin K2 (menaquinone-7) nanoemulsions modified with sialic acid-cholesterol conjugate.
Shi J1, Zhou S1, Kang L1, Ling H1, Chen J2, Duan L2, Song Y3, Deng Y4.
Author information
Abstract

Numerous studies have recently shown that vitamin K2 (VK2) has antitumor effects in a variety of tumor cells, but there are few reports demonstrating antitumor effects of VK2 in vivo. The antitumor effects of VK2 in nanoemulsions are currently not known. Therefore, we sought to characterize the antitumor potential of VK2 nanoemulsions in S180 tumor cells in the present study. Furthermore, a ligand conjugate sialic acid-cholesterol, with enhanced affinity towards the membrane receptors overexpressed in tumors, was anchored on the surface of the nanoemulsions to increase VK2 distribution to the tumor tissue. VK2 was encapsulated in oil-in-water nanoemulsions, and the physical and chemical stability of the nanoemulsions were characterized during storage at 25 °C. At 25 °C, all nanoemulsions remained physically and chemically stable with little change in particle size. An in vivo study using syngeneic mice with subcutaneously established S180 tumors demonstrated that intravenous or intragastric administration of VK2 nanoemulsions significantly suppressed the tumor growth. The VK2 nanoemulsions modified with sialic acid-cholesterol conjugate showed higher tumor growth suppression than the VK2 nanoemulsions, while neither of them exhibited signs of drug toxicity. In summary, VK2 exerted effective antitumor effects in vivo, and VK2 nanoemulsions modified with sialic acid-cholesterol conjugate enhanced the antitumor activity, suggesting that these VK2 may be promising agents for the prevention or treatment of tumor in patients.

fabian2
09.08.2019 kl 16:26 205

Hu Hei hvor det går med aksjekursen.....nå trenger vi flere studier....og et lite støttekjøp...
Redigert 09.08.2019 kl 16:47 Du må logge inn for å svare

"Trippel K2 er bedre enn alle andre , jeg er ikke i tvil om det"...... står det å lese på internett akkurat nå...... Er dette en konkurrent eller selveste Montgomery som er ute på skrytetur ?